Neuronetics Appoints Medtech Veteran Dan Reuvers As Chief Executive Officer, Succeeding Keith Sullivan

Neuronetics, Inc. announced the appointment of Dan Reuvers as its next President and Chief Executive Officer, effective March 23, 2026. He will also join the company’s Board of Directors on the same date. Reuvers succeeds Keith Sullivan, who will step down as CEO on March 23, 2026 and retire on March 31, 2026 after leading the company for more than five years.

"I am honored and excited to be joining the Neuronetics team," said Mr. Reuvers. "The Company’s leading TMS treatment platform, in conjunction with our national care delivery network provides a great foundation to build upon and drive profitable growth. There are millions of people suffering from depression who remain underserved by existing treatments. I am pleased to join the talented Neuronetics team and believe we are uniquely positioned to expand access to treatments that can restore hope for patients and their families.”

Neuronetics is a medical technology company focused on neurohealth disorders, best known for its NeuroStar Advanced Therapy. The leadership transition comes as the company continues to expand its presence in non-invasive treatments designed to improve quality of life for patients with neurological and mental health conditions.

"After a comprehensive search, the Board is pleased to appoint Dan Reuvers as our next President and CEO," said Rob Cascella, Neuronetics' Chairman of the Board. "Dan is a proven public company CEO with more than three decades of experience building and scaling medical technology businesses. He brings a strong track record of driving revenue growth, expanding market access, and successfully integrating acquisitions. Dan has done this across companies with commercial models that require deep relationships with prescribers, payers, and patients. His experience in both the device segment and direct billing models requiring effective revenue-cycle management is a strong fit for our business. His passion for meaningfully impacting underserved patient populations, combined with his demonstrated track record of delivering profitable growth, make him the ideal leader to drive the next stage of growth for the Company."

Reuvers brings extensive medtech leadership experience. He most recently served as President and CEO of Tactile Medical, where he led strong financial growth, increasing revenue from $187 million to approximately $300 million while achieving record earnings and cash flow. Prior to that, he spent 12 years at Integra LifeSciences, ultimately serving as Executive Vice President and President of Codman Specialty Surgical, a global neurosurgery division generating about $1 billion in revenue. Earlier in his career, he held leadership roles at Omni-Tract Surgical, Advanced Respiratory, Inc., and Vital Signs, Inc. He currently serves on the boards of Etac Group and Peerbridge Health.

Mr. Cascella continued, "On behalf of the entire Board, I want to thank Keith for his leadership over the past five years. Keith transformed Neuronetics from a single-product company into a vertically integrated mental health platform. Under his leadership, the Company completed the strategic acquisition of Greenbrook TMS, built a national clinic network that has delivered strong growth, significantly expanded insurance coverage and physician adoption of TMS, and positioned the Company for its next phase of growth. His leadership has made a lasting impact on this company and on the thousands of patients whose lives have been improved through the treatments we provide. We wish him well in his retirement.”

As part of his employment package, Reuvers received an inducement grant of 1.5 million restricted stock units. The award will vest in roughly equal portions on the first, second, and third anniversaries of his start date, subject to continued employment and the terms of the company’s 2020 Inducement Incentive Plan. The grant was approved by the Board of Directors, following the Compensation Committee's recommendation, in accordance with Nasdaq listing rules as a material inducement to his employment.